Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.

Alzheimers Dement · 2024 · PMC11095426 · PMID 38491912

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0870

boldest claim

The sentences

highly significantp < 0.0001actually significant

In this model, %p‐tau217 was highly significant ( p < 0.0001), and a 3% point (approximately 1 SD in the CL < = 25 group) higher %p‐tau217 was associated with an odds ratio of 5.4 (95% CI: 4.1 to 7.2) for identifying brain amyloidosis.

also in 132,142 other papers

did not reach statistical significancep = 0.087so close (0.05 < p ≤ 0.1)

While the increase in CL values did not reach statistical significance when corrected for multiple comparisons of the four different A/%pT217 classes ( p = 0.087, Bonferroni corrected t test, six total comparisons), if the two %pT217+ classes were combined into one, reducing the number of comparisons to three, CL values were statistically significantly higher in the A+/%pT217− versus A−/%pT217− subgroup ( p < 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.